A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary illness, including congenital heart disease (...

Descripción completa

Detalles Bibliográficos
Autores principales: Turti, Tatyana V, Baibarina, Elena N, Degtiareva, Elena A, Keshishyan, Elena S, Lobzin, Yurii V, Namazova-Вaranova, Leyla S, Prodeus, Andrey P, Gudkov, Konstantin M, Kruglova, Anna I, Schulz, Gregory A, Notario, Gerard F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532356/
https://www.ncbi.nlm.nih.gov/pubmed/22943074
http://dx.doi.org/10.1186/1756-0500-5-484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532356/
https://www.ncbi.nlm.nih.gov/pubmed/22943074
http://dx.doi.org/10.1186/1756-0500-5-484

Ejemplares similares